Clinical Trial

Clinical Study on the Mass Balance of Clifutinib

Completed Phase 1
View on ClinicalTrials.gov →
Summary
To investigate the plasma total radioactivity PK characteristics of male healthy subjects after a single oral administration of \[14C\]Clifutinib, the distribution of total radioactivity in whole blood and plasma, and to determine the main excretion and metabolic pathways.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-29.
Status change: Not Yet Recruiting → Completed 2026-01-14
Trial Details
NCT Number NCT07211165
Lead Sponsor Sunshine Lake Pharma Co., Ltd.
Conditions Healthy Adult Male
Enrollment 6 participants
Start Date 2025-09-29
Primary Completion 2025-11-05 (estimated)
Study Completion 2025-11-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-16